Jelena Bila

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 316 citations

Hematological Malignancy, Oncology, Dexamethasone Versus Pomalidomide +7

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 310 citations · Full text

Hematological Malignancy, Once-per-week Selinexor, Medicine +7

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability

Tilmann Bochtler, Ute Hegenbart, Friedrich W. Cremer et al. · Blood · 2008 · 111 citations

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics

Friedrich W. Cremer, Jelena Bila, Isabelle Buck et al. · Genes Chromosomes and Cancer · 2005 · 89 citations

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

Meral Beksaç, Güldane Cengiz Seval, Nicholas Kanellias et al. · Haematologica · 2019 · 86 citations · Full text